Empowered Patient Podcast

Lillian Phelps, Senior Director of Product Management, Availity shines light on the new HHS rules about price transparency for hospitals and health plans. These organizations now need to publish their standard rates as well as their contracted rates along with pricing for bundled services for over 70 specific services. As the nation's largest health information network, Availity works with providers and health plans to enable real-time generation of understandable data for patients and healthcare providers to inform better medical decisions.

@availity #pricetransparency

Availity.com

Listen to the podcast here

Lillian Phelps, Senior Director of Product Management, Availity shines light on the new HHS rules about price transparency for hospitals and health plans. These organizations now need to publish their standard rates as well as their contracted rates along with pricing for bundled services for over 70 specific services. As the nation's largest health information network, Availity works with providers and health plans to enable real-time generation of understandable data for patients and healthcare providers to inform better medical decisions.

@availity #pricetransparency

Availity.com

Download the transcript here

Ian Chan, CEO, Abpro is developing a drug which is a COVID-19 neutralizing antibody that has demonstrated strong binding affinity for COVID-19 in a Phase 2/3 global trial. Using the Diverse Immune Platform, an advanced antibody discovery platform, Abpro is drawing on years of successful work developing neutralizing monoclonal antibody therapies for treating traditionally difficult to access cancers, eye disease and autoimmune diseases. In addition to vaccines, COVID-19 therapeutics are essential for keeping the disease from progressing particularly for those most at risk.

@abpro #COVID19 #antibodytherapies #monoclonalantibodies

Abpro.com

Listen to the podcast here

Ian Chan, CEO, Abpro is developing a drug which is a COVID-19 neutralizing antibody that has demonstrated strong binding affinity for COVID-19 in a Phase 2/3 global trial. Using the Diverse Immune Platform, an advanced antibody discovery platform, Abpro is drawing on years of successful work developing neutralizing monoclonal antibody therapies for treating traditionally difficult to access cancers, eye disease and autoimmune diseases. In addition to vaccines, COVID-19 therapeutics are essential for keeping the disease from progressing particularly for those most at risk.

@abpro #COVID19 #antibodytherapies #monoclonalantibodies

Abpro.com

Download the transcript here

Hope Johnson, Administrator Perioperative Services, Lehigh Valley Health Network has deployed the Vocera Ease app to facilitate updates for family members about patient progress in surgery. Since they began implementing this solution in 2017, LVNH was prepared for the increased restrictions from COVID-19 on the ability of doctors and nurses to communicate about patient status. In addition to using this app for surgery patients, value is also being seen in situations requiring lengthy procedures or for patients in intensive care.

@lvhn #Vocera #COVID19

LVHN.org

Listen to the podcast here

Hope Johnson, Administrator Perioperative Services, Lehigh Valley Health Network has deployed the Vocera Ease app to facilitate updates for family members about patient progress in surgery. Since they began implementing this solution in 2017, LVNH was prepared for the increased restrictions from COVID-19 on the ability of doctors and nurses to communicate about patient status. In addition to using this app for surgery patients, value is also being seen in situations requiring lengthy procedures or for patients in intensive care.

@lvhn #Vocera #COVID19

LVHN.org

Download the transcript here

Joseph Sardano, Founder and CEO, Sensus Healthcare presents compelling data on the effectiveness of a non-surgical alternative to Mohs surgery for treating skin cancer and keloids. Using Superficial Radiation Therapy otherwise known as photon radiotherapy, the Sensus SRT system allows for non-invasive treatments without leaving a scar. In the age of COVID-19, dermatologists are finding this an excellent alternative to surgery particularly to treat those over 65 with pre-existing conditions.

@Sensushealth #skincancer #Keloid #Mohs #SRT #COVID19

Sensushealthcare.com

Listen to the podcast here

Joseph Sardano, Founder and CEO, Sensus Healthcare presents compelling data on the effectiveness of a non-surgical alternative to Mohs surgery for treating skin cancer and keloids. Using Superficial Radiation Therapy otherwise known as photon radiotherapy, the Sensus SRT system allows for non-invasive treatments without leaving a scar. In the age of COVID-19, dermatologists are finding this an excellent alternative to surgery particularly to treat those over 65 with pre-existing conditions.

@Sensushealth #skincancer #Keloid #Mohs #SRT #COVID19

Sensushealthcare.com

Download the transcript here

Dr. Saran Saund, Chief Business Officer, Oncotelic Therapeutics is an immuno-oncology company dedicated to developing RNA cancer therapies for melanoma and pancreatic cancer using their nano molecular therapy platform. Using AI they recently screened several of their own molecules and ethnobotanicals for COVID-19. As a result Oncotelic has developed a compound based on an ancient ayurvedic artemisinin-based therapy using the active ingredient from the plant artemisia, also known as sweet wormwood. The tablet formulation of ARTIVeda would allow for efficient distribution to a global audience at a fraction of the cost of current therapies like Remdesivir.

#Oncotelic #COVID19 #COVIDTherapies #ARTIVeda

Oncotelic.com

Listen to the podcast here

Dr. Saran Saund, Chief Business Officer, Oncotelic Therapeutics is an immuno-oncology company dedicated to developing RNA cancer therapies for melanoma and pancreatic cancer using their nano molecular therapy platform. Using AI they recently screened several of their own molecules and ethnobotanicals for COVID-19. As a result Oncotelic has developed a compound based on an ancient ayurvedic artemisinin-based therapy using the active ingredient from the plant artemisia, also known as sweet wormwood. The tablet formulation of ARTIVeda would allow for efficient distribution to a global audience at a fraction of the cost of current therapies like Remdesivir.

#Oncotelic #COVID19 #COVIDTherapies #ARTIVeda

Oncotelic.com

Download the transcript here